Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Niacinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.96 |
| ▸ | F3 | P13726 | 1/20 | 0.96 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.96 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.96 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.96 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.96 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.96 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.96 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.63 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.63 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacinamide SCHEMBL11870926 | 1.00 | F7 (0.96) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL2926 | 0.98 | — | — | |
| Niacinamide SCHEMBL19978192 | 0.98 | — | — | |
| Niacinamide SCHEMBL29624874 | 0.98 | — | — | |
| Niacinamide SCHEMBL460466 | 0.98 | F7 (1.00) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL25366418 | 0.96 | — | — | |
| Niacinamide SCHEMBL9373225 | 0.96 | F7 (0.96) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL1220080 | 0.96 | F7 (0.96) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL20723610 | 0.96 | — | — | |
| Niacinamide SCHEMBL226257 | 0.96 | F7 (0.96) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709842-A1 | SERUM-FREE AND XENO-FREE CULTURE MEDIUM FOR EXPANDING MESENCHYMAL STEM CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2026-03-18 | — | — | EP | disclosed |
| US-12359173-B2 | Serum-free and xeno-free culture medium for expanding mesenchymal stem cells | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-07-15 | — | — | US | disclosed |
| CN-119684381-A | Crystalline forms of nicotinamide riboside furanoside salts and nutritional supplements and pharmaceutical compositions containing same | 生物合成股份公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119462782-A | Method for producing nicotinamide riboside salts, nicotinamide riboside salts per se and use thereof | 生物合成股份公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024229624-A1 | SERUM-FREE AND XENO-FREE CULTURE MEDIUM FOR EXPANDING MESENCHYMAL STEM CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-11-14 | — | — | WO | disclosed |
| US-20240368554-A1 | SERUM-FREE AND XENO-FREE CULTURE MEDIUM FOR EXPANDING MESENCHYMAL STEM CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| CN-1918127-B | New cyclocompound having 4-pyridylalkylthio group to which substituted or unsubstituted amino group is introduced | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2012-02-15 | — | — | CN | disclosed |
| CN-1918127-A | New cyclocompound having 4-pyridylalkylthio group to which sustituted or unsubstituted amino group is introduced | SANTEN PHARMACEUTICAL CO LTD (JP) | 2007-02-21 | — | — | CN | disclosed |
| US-20040235084-A1 | Novel agents for replacement of NAD+/NADH system in enzymatic reactions | ENERGY, UNITED STATES DEPARTMENT OF | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235084-A1 | Novel agents for replacement of NAD+/NADH system in enzymatic reactions | NQO1, NADK, ME2 | F7 2187/4885F3 827/4885SARM1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.